110 related articles for article (PubMed ID: 8083348)
41. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
Kimoto Y
Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
[TBL] [Abstract][Full Text] [Related]
42. Biodistribution of human MHC non-restricted TALL-104 killer cells in healthy and tumor bearing mice.
Cesano A; Visonneau S; Tran T; Santoli D
Int J Oncol; 1999 Feb; 14(2):245-51. PubMed ID: 9917498
[TBL] [Abstract][Full Text] [Related]
43. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia.
Benyunes MC; Massumoto C; York A; Higuchi CM; Buckner CD; Thompson JA; Petersen FB; Fefer A
Bone Marrow Transplant; 1993 Aug; 12(2):159-63. PubMed ID: 8401364
[TBL] [Abstract][Full Text] [Related]
44. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
[TBL] [Abstract][Full Text] [Related]
45. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
Gregg EO; Gregg IC; Green I
Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265
[TBL] [Abstract][Full Text] [Related]
46. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
[TBL] [Abstract][Full Text] [Related]
47. Cell cycle assessment of adoptive transferred lymphokine activated killer cells.
Watanabe R; Tanaka N; Naomoto Y; Moreira LF; Orita K
Jpn J Clin Oncol; 1994 Apr; 24(2):59-65. PubMed ID: 8158860
[TBL] [Abstract][Full Text] [Related]
48. Analysis of the colonization of unirradiated and irradiated SCID mice by human lymphoma and non-malignant lymphoid cells.
Zubair AC; Ali SA; Rees RC; Goepel JR; Winfield DA; Goyns MH
Leuk Lymphoma; 1996 Aug; 22(5-6):463-71. PubMed ID: 8882960
[TBL] [Abstract][Full Text] [Related]
49. Effects of immunotherapy on experimental immunodeficiency-related lymphoproliferative disease.
Randhawa PS; Whiteside TL; Zeevi A; Elder EM; Rao AS; Demetris AJ; Weng X; Valdivia LA; Rakela J; Nalesnik MA
Transplantation; 1998 Jan; 65(2):264-8. PubMed ID: 9458027
[TBL] [Abstract][Full Text] [Related]
50. OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL.
Tomkinson B; Bendele R; Giles FJ; Brown E; Gray A; Hart K; LeRay JD; Meyer D; Pelanne M; Emerson DL
Leuk Res; 2003 Nov; 27(11):1039-50. PubMed ID: 12859997
[TBL] [Abstract][Full Text] [Related]
51. Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemia.
Lemoli RM; Parisi S; Curti A
Exp Hematol; 2017 Jan; 45():10-16. PubMed ID: 27826123
[TBL] [Abstract][Full Text] [Related]
52. Gene therapy with immunotoxins.
Vallera DA
Methods Mol Biol; 2001; 166():235-46. PubMed ID: 11217370
[No Abstract] [Full Text] [Related]
53. Survival and tissue distribution of human T-cell clones in SCID mice.
Abonour R; Cigel FK; Schell K; Barnstable CS; Sabatini LM; Malkovska V
J Immunother Emphasis Tumor Immunol; 1995 Jul; 18(1):10-8. PubMed ID: 8535566
[No Abstract] [Full Text] [Related]
54. Natural Killer Cell-Based Immunotherapy in Acute Myeloid Leukemia: Lessons for the Future.
Muntasell A; López-Botet M
Clin Cancer Res; 2016 Apr; 22(8):1831-3. PubMed ID: 26903071
[TBL] [Abstract][Full Text] [Related]
55. Visualizing the kinetics of tumor-cell clearance in living animals.
Sweeney TJ; Mailänder V; Tucker AA; Olomu AB; Zhang W; Cao Ya; Negrin RS; Contag CH
Proc Natl Acad Sci U S A; 1999 Oct; 96(21):12044-9. PubMed ID: 10518573
[TBL] [Abstract][Full Text] [Related]
56. Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab.
Sahin I; George A; Zhang S; Huntington KE; Ordulu Z; Zhou L; El-Deiry WS
Oncotarget; 2021 Oct; 12(21):2131-2146. PubMed ID: 34676046
[TBL] [Abstract][Full Text] [Related]
57. Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors.
Gomez GG; Read SB; Gerschenson LE; Santoli D; Zweifach A; Kruse CA
Neuro Oncol; 2004 Apr; 6(2):83-95. PubMed ID: 15134622
[TBL] [Abstract][Full Text] [Related]
58. Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice.
Visonneau S; Cesano A; Torosian MH; Miller EJ; Santoli D
Am J Pathol; 1998 May; 152(5):1299-311. PubMed ID: 9588898
[TBL] [Abstract][Full Text] [Related]
59. Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy.
Cesano A; Visonneau S; Cioé L; Clark SC; Santoli D
Cancer Immunol Immunother; 1995 Mar; 40(3):139-51. PubMed ID: 7728772
[TBL] [Abstract][Full Text] [Related]
60. Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach.
Cesano A; Visonneau S; Cioé L; Clark SC; Rovera G; Santoli D
J Clin Invest; 1994 Sep; 94(3):1076-84. PubMed ID: 8083348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
